This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goodman, V. L. Articles by Pazdur, R. Search for Related Content PubMed PubMed Citation Articles by Goodman, V. L. Articles by Pazdur, R.

Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

Authors' Affiliations: ¹ Division of Drug Oncology Products; ² Office of Clinical Pharmacology, Division of Clinical Pharmacology 5; ³ Offices of Pharmaceutical Science, ⁴ Biostatistics, and ⁵ Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland

Requests for reprints: Vicki L. Goodman, Food and Drug Administration, Division of Drug Oncology Products, Room 2139, Building 22, 10903 New Hampshire Avenue, Silver Spring, MD 20903. Phone: 301-796-1361; Fax: 301-796-9845; E-mail: vicki.goodman{at}fda.hhs.gov.

Abstract

Purpose: To describe the Food and Drug Administration (FDA) review and approval of sunitinib malate (Sutent). Sunitinib received regular approval for the treatment of gastrointestinal stromal tumor (GIST) after disease progression or intolerance to imatinib mesylate (Gleevec). Additionally, sunitinib received accelerated approval for the treatment of advanced renal cell carcinoma.

Experimental Design: For the GIST indication, FDA reviewed data from a randomized, placebo-controlled trial with supportive evidence from a single-arm study. For the advanced renal cell carcinoma indication, FDA reviewed data from two single-arm studies of patients with cytokine-refractory metastatic renal cell carcinoma.

Results: In patients with imatinib refractory or intolerant GIST, time-to-tumor progression of sunitinib-treated patients was superior to that of placebo-treated patients. Median time-to-tumor progression of sunitinib-treated patients was 27.3 weeks, compared with 6.4 weeks for placebo-treated patients (P < 0.0001). Partial responses were observed in 6.8% of sunitinib-treated patients. In patients with metastatic renal cell carcinoma, partial responses were observed in 25.5% (95% confidence interval, 17.5, 34.9) and 36.5% (95% confidence interval, 24.7, 49.6) of patients treated with sunitinib. Median response durations were 27.1 and 54 weeks. The most common adverse events attributed to sunitinib included diarrhea, mucositis, skin abnormalities, and altered taste. Reductions in left ventricular ejection fraction and severe hypertension were also more common in sunitinib-treated patients.

Conclusions: On January 26, 2006, the FDA approved sunitinib for the treatment of patients with imatinib refractory or intolerant GIST. Accelerated approval was granted for the treatment of advanced renal cell carcinoma.

This article has been cited by other articles:

				D. B. Costa, K.-S. H. Nguyen, B. C. Cho, L. V. Sequist, D. M. Jackman, G. J. Riely, B. Y. Yeap, B. Halmos, J. H. Kim, P. A. Janne, et al. Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib Clin. Cancer Res., November 1, 2008; 14(21): 7060 - 7067. [Abstract] [Full Text] [PDF]

				B. P. Schneider, M. Wang, M. Radovich, G. W. Sledge, S. Badve, A. Thor, D. A. Flockhart, B. Hancock, N. Davidson, J. Gralow, et al. Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100 J. Clin. Oncol., October 1, 2008; 26(28): 4672 - 4678. [Abstract] [Full Text] [PDF]

				B. M. Yan, G. G. Kaplan, S. Urbanski, C. L. Nash, and P. L. Beck Epidemiology of Gastrointestinal Stromal Tumors in a Defined Canadian Health Region: A Population-Based Study International Journal of Surgical Pathology, July 1, 2008; 16(3): 241 - 250. [Abstract] [PDF]

				F. Navid, R. Christensen, P. Minkin, C. F Stewart, W. L Furman, and S. Baker Stability of Sunitinib in Oral Suspension Ann. Pharmacother., July 1, 2008; 42(7): 962 - 966. [Abstract] [Full Text] [PDF]

				J. Schlom, J. L. Gulley, and P. M. Arlen Paradigm Shifts in Cancer Vaccine Therapy Experimental Biology and Medicine, May 1, 2008; 233(5): 522 - 534. [Abstract] [Full Text] [PDF]

				S. Hu, H. Niu, P. Minkin, S. Orwick, A. Shimada, H. Inaba, G. V.H. Dahl, J. Rubnitz, and S. D. Baker Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia Mol. Cancer Ther., May 1, 2008; 7(5): 1110 - 1120. [Abstract] [Full Text] [PDF]

				D. T. Dang, S. Y. Chun, K. Burkitt, M. Abe, S. Chen, P. Havre, N. J. Mabjeesh, E. I. Heath, N. J. Vogelzang, M. Cruz-Correa, et al. Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor Inhibition Cancer Res., March 15, 2008; 68(6): 1872 - 1880. [Abstract] [Full Text] [PDF]

				D. Huang, Y. Ding, W.-M. Luo, S. Bender, C.-N. Qian, E. Kort, Z.-F. Zhang, K. VandenBeldt, N. S. Duesbery, J. H. Resau, et al. Inhibition of MAPK Kinase Signaling Pathways Suppressed Renal Cell Carcinoma Growth and Angiogenesis In vivo Cancer Res., January 1, 2008; 68(1): 81 - 88. [Abstract] [Full Text] [PDF]

				J. C. McAuliffe, A. J.F. Lazar, D. Yang, D. M. Steinert, W. Qiao, P. F. Thall, A. K. Raymond, R. S. Benjamin, and J. C. Trent Association of Intratumoral Vascular Endothelial Growth Factor Expression and Clinical Outcome for Patients with Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate Clin. Cancer Res., November 15, 2007; 13(22): 6727 - 6734. [Abstract] [Full Text] [PDF]

				W. J. van Heeckeren, J. Ortiz, M. M. Cooney, and S. C. Remick Hypertension, Proteinuria, and Antagonism of Vascular Endothelial Growth Factor Signaling: Clinical Toxicity, Therapeutic Target, or Novel Biomarker? J. Clin. Oncol., July 20, 2007; 25(21): 2993 - 2995. [Full Text] [PDF]

				J. Schlom, P. M. Arlen, and J. L. Gulley Cancer Vaccines: Moving Beyond Current Paradigms Clin. Cancer Res., July 1, 2007; 13(13): 3776 - 3782. [Abstract] [Full Text] [PDF]